Interleukin-2 in the Treatment of Renal Cell Carcinoma and Malignant Melanoma

This publication has 56 references indexed in Scilit:

• Cancer Regression and Autoimmunity in Patients After Clonal Repopulation with Antitumor Lymphocytes
  Science, 2002
• INTERLEUKIN 10 PROTECTS ACTIVATED HUMAN T LYMPHOCYTES AGAINST GROWTH FACTOR WITHDRAWAL-INDUCED CELL DEATH BUT ONLY ANTI-FAS ANTIBODY CAN PREVENT ACTIVATION-INDUCED CELL DEATH
  Cytokine, 1996
• Neonatal Tolerance Revisited: Turning on Newborn T Cells with Dendritic Cells
  Science, 1996
• Expansion of Peripheral Blood Natural Killer Cells Correlates with Clinical Outcome in Cancer Patients Receiving Recombinant Subcutaneous lnterleukin-2 and Interferon-α-2
  Tumor Biology, 1993
• Interleukin-2 dose, blood monocyte and CD25+ lymphocyte counts as predictors of clinical response to interleukin-2 therapy in patients with renal cell carcinoma
  Cancer Immunology, Immunotherapy, 1991
• Autologous tumor-specific cytotoxic T lymphocytes in the infiltrate of human metastatic melanomas. Activation by interleukin 2 and autologous tumor cells, and involvement of the T cell receptor.
  The Journal of Experimental Medicine, 1988
• A Progress Report on the Treatment of 157 Patients with Advanced Cancer Using Lymphokine-Activated Killer Cells and Interleukin-2 or High-Dose Interleukin-2 Alone
  New England Journal of Medicine, 1987
• Observations on the Systemic Administration of Autologous Lymphokine-Activated Killer Cells and Recombinant Interleukin-2 to Patients with Metastatic Cancer
  New England Journal of Medicine, 1985
• Successful immunotherapy of natural killer-resistant established pulmonary melanoma metastases by the intravenous adoptive transfer of syngeneic lymphocytes activated in vitro by interleukin 2.
  The Journal of Experimental Medicine, 1984
• T-cell-derived helper factor allows in vivo induction of cytotoxic T cells in nu/nu mice
  Nature, 1980